

# TREATMENT MEDICATIONS

## Drugs that slow the disease process:

- Aducanumab(Aduhelm): IV infusion to remove beta-amyloid (protein plaques) from the brain.
  - FDA approved but discontinued in 2024 by manufacturer
- Donanemab(Kisunla): IV infusion to remove beta-amyloid.
  - Traditional FDA approval
- Lecanemab (Leqembi): anti-amyloid IV infusion. Removes beta-amyloid
  - Traditional FDA approval

 **Aduhelm®**  
(aducanumab-avwa) | 100 mg/mL injection, for intravenous use

 **kisunla™**  
(donanemab-azbt)  
injection for IV infusion  
350 mg/20 mL

 **LEQEMBI®**  
(lecanemab-irmb) 100 mg/mL  
INJECTION FOR INTRAVENOUS USE

 **REXULTI®**  
brexpiprazole  
2mg tablets

 **Namenda XR™**  
(memantine HCl) extended release capsules  
7 mg, 14 mg, 21 mg, 28 mg

 **EXELON® PATCH**  
(rivastigmine)

## Drugs that manage symptoms:

- Cholinesterase inhibitors-prevent breakdown of acetylcholine to preserve communication between nerve cells
  - Aricept, Exelon, Razadyne
- Glutamate regulators – regulating glutamate activity to preserve neural communication.
  - Namenda
- Cholinesterase inhibitor + glutamate regulatory – increased neural communication and processing
  - Namzaric
- Behavior and psychiatric management
  - Belsomra – insomnia
  - Rexulti – antipsychotic for agitation



# COGNITIVE THERAPY

- Cognitive testing and dementia staging
- Exercises and compensatory strategies for
  - Memory
  - Problem – solving
  - Attention
  - Communication
  - Behaviors
- Education for patient and family on disease process.
- Resources and supports for patients and families.

